MedTrace Logo

What is the Prognostic Value of HALP Score, Monocytopenia, Hypofibrinogenemia, and AST/ALT Ratio in Patients With Myelodysplastic Syndromes

NCT07210034 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-10-07

No results posted yet for this study

Summary

to investigate prognostic significance of many factors in MDS including HALP score ( haemoglobin level, albumin level, lymphocyte, platelets), monocytopenia, hyperfibrinogenemia and AST/ALT ratio in patients with MDS at Assiut University Hospital.

And to study overall survival and leukemia free survival rates in MDS patients.

Conditions

  • Myelo Dysplastic Syndrome

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2028-01-01
Completion
2028-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07210034 on ClinicalTrials.gov